nicergoline
Trade name: Sermion
Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other ergolines, such as ergotamine, nicergoline is not associated with cardiac fibrosis. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Dec 23, 2019 (NCT04176367)
Timeline
Indications
Mechanism of action
- Alpha-1b adrenergic receptorINHIBITOR
ADRA1B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNicergoline ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05551182 | Phase 3 | Jan 31, 2023 | Burapha University, Government of Thailand, Silpakorn University |
| NCT04176367 | Phase 1 | Dec 23, 2019 | Pfizer |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Burapha University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Government of Thailand | Government | 1 | 1 | 1 | 2023 |
| Pfizer | For profit | 1 | 1 | 1 | 2019 |
| Silpakorn University | Academic/Hospital | 1 | 0 | 1 | 2023 |